Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.810
+0.340 (9.80%)
Apr 9, 2026, 2:29 PM EDT - Market open
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$270,258
Profits / Employee
-$401,003
Market Cap
1.57B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Wave Life Sciences | 317 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Zenas BioPharma | 167 |
| Monte Rosa Therapeutics | 150 |
| Maze Therapeutics | 141 |
| Olema Pharmaceuticals | 131 |
IOVA News
- 19 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
- 6 weeks ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 6 weeks ago - Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Benzinga
- 6 weeks ago - Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates - GlobeNewsWire
- 6 weeks ago - Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - GlobeNewsWire
- 2 months ago - Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewsWire